Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospital-based rheumatologists

Journal of Rheumatology

Volumn 31, Issue 7, 2004, Pages 1297-1304

  Guillemin, Francis ^a   Durieux, Stephanie ^b   Daurès, Jean Pierre ^c   Lafuma, Antoine ^d   Saraux, Alain ^e   Sibilia, Jean ^f   Bourgeois, Pierre ^g   Sany, Jacques ^h  

^a Faculty of Medicine

^b Hopital Saint Michel   (France)

^c UNIV MONTPELLIER   (France)

^d CEMKA EVAL   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h LAPEYRONIE HOSPITAL   (France)

Author keywords

Direct costs; Disease activity; Disease severity; Hospitalization; Rheumatoid arthritis; Social costs

Indexed keywords

ANTIBODY; AZATHIOPRINE; CD4 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TIOPRONIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ABSENTEEISM; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSULTATION; COST OF ILLNESS; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; FEMALE; FRANCE; FUNCTIONAL ASSESSMENT; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MULTICENTER STUDY; PENSION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOCIAL INSURANCE; UNITED STATES;

AGED; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; ECONOMICS, HOSPITAL; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATOLOGY;

EID: 3042852094     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Guillemin F, Saraux A, Guggenbuhl P, et al. Prévalence de la polyarthrite rhumatoïde et des spondylarthropathies en France en 2001. Rev Rhum Mal Osteoartic 2002;69:1014-38.
2. Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002;14:121-6.
3. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.
4. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996;23 Suppl 44:47-51.
5. Van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma W. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998;37:837-47.
6. Gabriel S, Tugwell T, O'Brien B, et al. Report of the OMERACT Task Force on Economic Evaluation. J Rheumatol 1999;26:203-6.
7. Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002;61:370-3.
8. Sany J, Bourgeois P, Saraux A, et al. Characteristics of patients with rheumatoid arthritis (RA) in France: a study of 1109 patients managed by hospital-based rheumatologists. Ann Rheum Dis 2003;62:S67
9. Felson D, Anderson J, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-4.
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
12. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
13. Union des Caisses Nationales de Sécurité Sociale. Nomenclature Générale des actes professionnels. Paris: UCANSS; 2000.
14. Union des Caisses Nationales de Sécurité Sociale. Nomenclature Générale des actes professionnels. Tarif Interministériel des Prestations Sanitaires. Paris: UCANSS; 2000-2001.
15. Base Nationale PMSI 1999/Echelle Nationale de coût en point ISA - Direction des Hôpitaux, Ministère du Travail, de l'Emploi et de la Solidarité. [Internet]. 2001 [Cited March 3, 2004]. Available from: www.le-pmsi.org/mco/infos/plfss2001.html
16. Le dictionnaire Vidal. Issy les Moulineaux, France: Vidal: 2000.
17. Lubeck DP. A review of the direct costs of rheumatoid arthritis. Managed care versus fee-for-service settings. Pharmacoeconomics 2001;19:811-8.
18. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
19. Maravic M, Bozonnat MC, Sevezan A, et al. Preliminary evaluation of medical outcomes (including quality of life) and costs in incident RA cases receiving hospital-based multidisciplinary management. Joint Bone Spine 2000;67:425-33.
20. Girard F, Guillemin F, Novella JL, et al. Health-care use by rheumatoid arthritis patients compared with non-arthritic subjects. Rheumatology Oxford 2002;41:167-75.
21. Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-15.
22. Stone CE. The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984;11:819-27.
23. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein W. The costs of rheumatoid arthritis. A patient oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
24. Merkesdal S, Ruof J, Schoffski O, Bemitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis. Arthritis Rheum 2001;44:528-34.
25. Cooper NJ, Mugford M, Symmons DP, Barrett EM, Scott DG. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology Oxford 2002;41:767-74.
26. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9.
27. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9.
28. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
29. Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM; Arthritis Cost and Outcome Project Group. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002;61:818-21.
30. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-81.
31. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
32. Ruof J, Hulsemann JL, Mittendorf T, et al. Costs of rheumatoid, arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-9.
33. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
34. Aletaha D, Smolen JS. Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. Arthritis Rheum 2002;47:181-8.
35. Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002;47:285-90.
36. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-64.
37. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.